A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Trial Profile

A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Oct 2016 Status changed from recruiting to completed.
    • 19 Jul 2011 Planned End Date changed from 1 Mar 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Celgene Corporation expect enrollment to be completed in 2011, according to a Celgene media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top